LDLR and gastric cancer: We identified that lipid-lowering variants of ANGPTL3 (OR 0.83; 95% CI: 0.72 to 0.95; p-IVW=7.65×10-3, FDR=3.53×10-2) and LDLR (OR 0.83; 95% CI: 0.82 to 0.93; p-IVW=7.39×10-5, FDR=6.52×10-4) were associated with decreased risks of colorectal cancers, and ANGPTL3 (OR 0.13; 95% CI: 0.04 to 0.41; p-IVW=4.64×10-4, FDR=2.91×10-3) was also associated with lower risks of gastric cancers.